Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: Implications for adoptive immunotherapy after allogeneic stem cell transplantation

Haematologica

Volumn 95, Issue 9, 2010, Pages 1579-1586

  Kuçi, Selim ^a   Rettinger, Eva ^a   Voß, Bernhard ^a   Weber, Gerrit ^a   Stais, Miriam ^a   Kreyenberg, Hermann ^a   Willasch, Andre ^a   Kuçi, Zyrafete ^a   Koscielniak, Ewa ^b   Klöss, Stephan ^a   von Laer, Dorothee ^c   Klingebiel, Thomas ^a   Bader, Peter ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b OLGAHOSPITAL   (Germany)

^c INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

CIK; Lysis; NKG2D; Rhabdomyosarcoma

Indexed keywords

BINDING PROTEIN; CASPASE 3; CD137 ANTIGEN; CD1D ANTIGEN; CD3 ANTIGEN; CD69 ANTIGEN; HLA A ANTIGEN; HLA B ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; NATURAL KILLER CELL RECEPTOR NKG2D; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UL16 BINDING PROTEIN; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL COMPOSITION; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOLYSIS; CYTOTOXICITY; EFFECTOR CELL; EMBRYO; EMBRYO CELL; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL; MEMORY T LYMPHOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN PROTEIN INTERACTION; RHABDOMYOSARCOMA; SARCOMA CELL;

CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; RHABDOMYOSARCOMA; TRANSPLANTATION, HOMOLOGOUS;

EID: 77956823289     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.019885     Document Type: Article

References (42)

1. Pastore G, Peris-Bonet R, Carli M, Martinez-Garcia C, Sanchez de TJ, Steliarova-Foucher E. Childhood soft tissue sarcomas incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42(13):2136-2149.
2. Carli M, Colombatti R, Oberlin O, Bisogno G, Treuner J, Koscielniak E, et al. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol. 2004;22 (23):4787-4794.
3. Breitfeld PP, Lyden E, Raney RB, Teot LA, Wharam M, Lobe T, et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol. 2001;23(4):225-233.
4. Pappo AS, Anderson JR, Crist WM, Wharam MD, Breitfeld PP, Hawkins D, et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol. 1999;17(11):3487-3493.
5. Koscielniak E, Harms D, Henze G, Jurgens H, Gadner H, Herbst M, et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol. 1999;17(12): 3706-3719.
6. Klingebiel T, Pertl U, Hess CF, Jurgens H, Koscielniak E, Potter R, et al. Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial. Med Pediatr Oncol. 1998;30(5):269-275.
7. Koscielniak E, Gross-Wieltsch U, Treuner J, Winkler P, Klingebiel T, Lang P, et al. Graftversus-Ewing sarcoma effect and long-term remission induced by haploidentical stemcell transplantation in a patient with relapse of metastatic disease. J Clin Oncol. 2005;23(1):242-244.
8. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood. 1996;88(4):1501-1508.
9. Bader P, Soerensen J, Jarisch A, Weber G, Kreyenberg H, Rettinger E, et al. Allogeneic stem cell transplantation in children and adolescents with high risk alveolar rhabdomyosarcoma. Bone Marrow Transplant. 2007;39 (Suppl. 1):74.
10. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells withpotent antitumor cell activity. J Exp Med. 1991;174(1):139-149.
11. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 1993;21(3):1673-1679.
12. Schmidt-Wolf IG, Lefterova P, Johnston V, Huhn D, Blume KG, Negrin RS. Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol. 1994;87(3):453-458.
13. Joshi PS, Liu JQ, Wang Y, Chang X, Richards J, Assarsson E, et al. Cytokineinduced killer T cells kill immature dendritic cells by TCR-independent and perforindependent mechanisms. J Leukoc Biol. 2006;80(6):1345-1353.
14. Alvarnas JC, Linn YC, Hope EG, Negrin RS. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2001;7(4):216-222.
15. Linn YC, Hui KM. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia. Leuk Lymphoma 2003;44(9):1457-1462.
16. Kornacker M, Moldenhauer G, Herbst M, Weilguni E, Tita-Nwa F, Harter C, et al. Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma. Int J Cancer. 2006;119(6):1377-1382.
17. Hongeng S, Petvises S, Worapongpaiboon S, Rerkamnuaychoke B, Pakakasama S, Jootar S. Generation of CD3+ CD56+cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int J Hematol. 2003;77(2):175-179.
18. Wongkajornsilp A, Sangsuriyong S, Hongeng S, Waikakul S, Asavamongkolkul A, Huabprasert S. Effective osteosarcoma cytolysis using cytokine-induced killer cells pre-inoculated with tumor RNA-pulsed dendritic cells. J Orthop Res. 2005;23(6): 1460-1466.
19. Kim HM, Lim J, Yoon YD, Ahn JM, Kang JS, Lee K, et al. Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int Immunopharmacol. 2007;7(13):1793-1801.
20. Mehta BA, Schmidt-Wolf IG, Weissman IL, Negrin RS. Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+killer cells. Blood. 1995;86(9):3493-3499.
21. Verneris MR, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 2004;103(8):3065-3072.
22. Linn YC, Wang SM, Hui KM. Comparative gene expression profiling of cytokineinduced killer cells in response to acute myloid leukemic and acute lymphoblastic leukemic stimulators using oligonucleotide arrays. Exp Hematol. 2005;33(6):671-681.
23. Baker J, Verneris MR, Ito M, Shizuru JA, Negrin RS. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood. 2001;97(10):2923-2931.
24. Verneris MR, Ito M, Baker J, Arshi A, Negrin RS, Shizuru JA. Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant. 2001;7(10):532-542.
25. Zhang YS, Yuan FJ, Jia GF, Zhang JF, Hu LY, Huang L, et al. CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol. 2005;11(22):3339-3345.
26. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2005;11(3):181-187.
27. Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, et al. Repeated infusions of donor-derived cytokineinduced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica. 2007;92(7): 952-959.
28. Koh MB, Prentice HG, Lowdell MW. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow Transplant. 1999;23(10):1071-1079.
29. Fehse B, Frerk O, Goldmann M, Bulduk M, Zander AR. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69). Br J Haematol. 2000; 109(3):644-651.
30. Hartwig UF, Nonn M, Khan S, Meyer RG, Huber C, Herr W. Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes. Bone Marrow Transplant. 2006;37(3):297-305.
31. Wehler TC, Nonn M, Brandt B, Britten CM, Grone M, Todorova M, et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood. 2007;109(1):365-373.
32. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med. 1998;187(12):2065-2072.
33. Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R, et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol. 1999;29(5):1656-1666.
34. Andre P, Biassoni R, Colonna M, Cosman D, Lanier LL, Long EO, et al. New nomenclature for MHC receptors. Nat Immunol. 2001;2(8):661.
35. Lopez-Botet M, Carretero M, Bellon T, Perez-Villar JJ, Llano M, Navarro F. The CD94/NKG2C-type lectin receptor complex in recognition of HLA class I molecules. Res Immunol. 1997;148(3):155-159.
36. Lanier LL. Natural killer cell receptor signaling. Curr Opin Immunol. 2003;15(3):308-314.
37. von Lilienfeld-Toal M, Nattermann J, Feldmann G, Sievers E, Frank S, Strehl J, Schmidt-Wolf IG. Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and show cytotoxic activity against myeloma cells. Clin Exp Immunol. 2006;144(3):528-533.
38. Roth P, Mittelbronn M, Wick W, Meyermann R, Tatagiba M, Weller M. Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. Cancer Res. 2007;67(8):3540-354.
39. Bouche M, Canipari R, Melchionna R, Willems D, Senni MI, Molinaro M. TGFbeta autocrine loop regulates cell growth and myogenic differentiation in human rhabdomyosarcoma cells. FASEB J. 2000;14(9):1147-1158.
40. Franceschetti M, Pievani A, Borleri G, Vago L, Fleischhauer K, Golay J, Introna M. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic TEMRA lymphocytes. Exp Hematol. 2009; 37(5):616-628.
41. Trapani JA, Smyth MJ. Functional significance of the perforin/granzyme cell death pathway. Nat Rev Immunol. 2002;2(10): 735-747.
42. Ozdemir O, Savasan S. Combinational IL-2/IL-15 induction does not further enhance IL-15-induced lymphokine-activated killer cell cytotoxicity against human leukemia/lymphoma cells. Clin Immunol. 2005;115(3):240-249.